Medical Services

Clinical Trials at Englewood Hospital: Oncology

Lung Cancer

EHMC IRB Study #: E-07-304

Principal Investigator:
Dr. Michael Schleider
Tel: 201-568-5250
MSCHLEIDE@aol.com

Study Coordinator:
Audrey Ades
Tel: 201-894-3603
Email: audrey.ades@ehmc.com

Sponsor:
National Cancer Institute - ECOG

Study Title:
E1505: A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB - IIIA Non-Small Cell Lung Cancer

Eligibility requirements:
Patients who are at least 18 years old with completely resected Stage IB - IIIA Non-Small Cell Lung Cancer who have not received any prior therapy.

Study objectives:
To evaluate the overall survival with chemotherapy with or without bevacizumab used in the adjuvant setting in patients with resected stage IB - IIIA non-small cell lung cancer

Summary of procedures:
The physician will select one of four protocol-approved standard chemotherapy regimens.  Then, the patient will be randomized to either Arm A (no bevacizumab ) or Arm B (bevacizumab in addition to the assigned chemotherapy.)  All regimens will be given in 3-week cycles for a total of 4 cycles.  All patients will be followed for response until progression and for survival for 10 years.

*Each listing only contains a summary of the study information.  Please contact the Principal Investigator or Study Coordinator for the full details on a particular study.